TipRanks
Xencor Inc (CH:XE9)
:XE9
Switzerland Market
XE9
Xencor
RESEARCH TOOLSreports

Xencor (XE9) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

XE9 Analyst Ratings

Strong Buy
13Ratings
Strong Buy
11 Buy
2 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Xencor
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

XE9 Stock 12 Month Forecast

Average Price Target

―
Based on 13 Wall Street analysts offering 12 month price targets for Xencor in the last 3 months. The average price target is CHF26.69 with a high forecast of CHF38.36 and a low forecast of CHF16.68. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF38.36Average Price TargetCHF26.69Lowest Price TargetCHF16.68
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on CH:XE9
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
CHF25.02
Buy
―
Reiterated
09/29/26
Wells Fargo Reaffirms Their Buy Rating on Xencor (XNCR)
Truist Financial Analyst forecast on CH:XE9
Gregory Renza
Truist Financial
Truist Financial
CHF22.52→CHF24.19
Buy
―
Reiterated
09/28/26
Analysts Offer Insights on Healthcare Companies: Xencor (NASDAQ: XNCR) and IQVIA Holdings (NYSE: IQV)
Wedbush Analyst forecast on CH:XE9
David Nierengarten
Wedbush
Wedbush
CHF25.02
Buy
―
Reiterated
09/25/26
Analysts Are Bullish on Top Healthcare Stocks: Staar Surgical (STAA), Xencor (XNCR)
Bank of America Securities Analyst forecast on CH:XE9
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF21.68
Hold
―
Reiterated
09/21/26
Xencor price target raised to $26 from $20 at BofAXencor price target raised to $26 from $20 at BofA
Barclays Analyst forecast on CH:XE9
Etzer Darout
Barclays
Barclays
CHF22.52→CHF29.19
Buy
―
Reiterated
09/11/26
Xencor (XNCR) Receives a Buy from Barclays
J.P. Morgan Analyst forecast on CH:XE9
Brian Cheng
J.P. Morgan
J.P. Morgan
CHF11.68→CHF17.51
Hold
―
Reiterated
09/03/26
Xencor price target raised to $21 from $14 at JPMorganXencor price target raised to $21 from $14 at JPMorgan
Raymond James Analyst forecast on CH:XE9
Sean McCutcheon
Raymond James
Raymond James
CHF38.36
Buy
―
Assigned
09/01/26
Xencor price target raised to $46 from $40 at Raymond JamesXencor price target raised to $46 from $40 at Raymond James
Cantor Fitzgerald Analyst forecast on CH:XE9
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
CHF36.7
Buy
―
Reiterated
08/10/26
Analysts' Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)
Piper Sandler Analyst forecast on CH:XE9
Edward Tenthoff
Piper Sandler
Piper Sandler
CHF27.52
Buy
―
Reiterated
08/06/26
Piper Sandler Remains a Buy on Xencor (XNCR)
William Blair Analyst forecast on CH:XE9
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Xencor Earns Buy Rating as XmAb541 and XmAb808 Advance Toward Differentiated Solid-Tumor Franchise
RBC Capital Analyst forecast on CH:XE9
Leonid Timashev
RBC Capital
RBC Capital
CHF15.85→CHF16.68
Buy
―
Reiterated
08/05/26
RBC Capital Sticks to Their Buy Rating for Xencor (XNCR)
TD Cowen Analyst forecast on CH:XE9
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/05/26
Xencor: Buy Rating Backed by XmAb819 Expansion and Immunology Pipeline Milestones Ahead of Key 2026–2027 Data Catalysts
Canaccord Genuity Analyst forecast on CH:XE9
John Newman
Canaccord Genuity
Canaccord Genuity
CHF31.69
Buy
―
Reiterated
08/05/26
Analyst John Newman Reiterates Buy on Xencor, Citing Late-Stage XmAb Pipeline, Non-Dilutive Cash Inflows and Royalties, and Sets $38 Price Target
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on CH:XE9
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
CHF25.02
Buy
―
Reiterated
09/29/26
Wells Fargo Reaffirms Their Buy Rating on Xencor (XNCR)
Truist Financial Analyst forecast on CH:XE9
Gregory Renza
Truist Financial
Truist Financial
CHF22.52→CHF24.19
Buy
―
Reiterated
09/28/26
Analysts Offer Insights on Healthcare Companies: Xencor (NASDAQ: XNCR) and IQVIA Holdings (NYSE: IQV)
Wedbush Analyst forecast on CH:XE9
David Nierengarten
Wedbush
Wedbush
CHF25.02
Buy
―
Reiterated
09/25/26
Analysts Are Bullish on Top Healthcare Stocks: Staar Surgical (STAA), Xencor (XNCR)
Bank of America Securities Analyst forecast on CH:XE9
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF21.68
Hold
―
Reiterated
09/21/26
Xencor price target raised to $26 from $20 at BofAXencor price target raised to $26 from $20 at BofA
Barclays Analyst forecast on CH:XE9
Etzer Darout
Barclays
Barclays
CHF22.52→CHF29.19
Buy
―
Reiterated
09/11/26
Xencor (XNCR) Receives a Buy from Barclays
J.P. Morgan Analyst forecast on CH:XE9
Brian Cheng
J.P. Morgan
J.P. Morgan
CHF11.68→CHF17.51
Hold
―
Reiterated
09/03/26
Xencor price target raised to $21 from $14 at JPMorganXencor price target raised to $21 from $14 at JPMorgan
Raymond James Analyst forecast on CH:XE9
Sean McCutcheon
Raymond James
Raymond James
CHF38.36
Buy
―
Assigned
09/01/26
Xencor price target raised to $46 from $40 at Raymond JamesXencor price target raised to $46 from $40 at Raymond James
Cantor Fitzgerald Analyst forecast on CH:XE9
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
CHF36.7
Buy
―
Reiterated
08/10/26
Analysts' Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)
Piper Sandler Analyst forecast on CH:XE9
Edward Tenthoff
Piper Sandler
Piper Sandler
CHF27.52
Buy
―
Reiterated
08/06/26
Piper Sandler Remains a Buy on Xencor (XNCR)
William Blair Analyst forecast on CH:XE9
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Xencor Earns Buy Rating as XmAb541 and XmAb808 Advance Toward Differentiated Solid-Tumor Franchise
RBC Capital Analyst forecast on CH:XE9
Leonid Timashev
RBC Capital
RBC Capital
CHF15.85→CHF16.68
Buy
―
Reiterated
08/05/26
RBC Capital Sticks to Their Buy Rating for Xencor (XNCR)
TD Cowen Analyst forecast on CH:XE9
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/05/26
Xencor: Buy Rating Backed by XmAb819 Expansion and Immunology Pipeline Milestones Ahead of Key 2026–2027 Data Catalysts
Canaccord Genuity Analyst forecast on CH:XE9
John Newman
Canaccord Genuity
Canaccord Genuity
CHF31.69
Buy
―
Reiterated
08/05/26
Analyst John Newman Reiterates Buy on Xencor, Citing Late-Stage XmAb Pipeline, Non-Dilutive Cash Inflows and Royalties, and Sets $38 Price Target
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
OVIDOvid Therapeutics
WSTWest Pharmaceutical Services
ZYMEZymeworks
SLDBSolid Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Xencor

3 Months
David NierengartenWedbush
Success Rate
8/12 ratings generated profit
67%
Average Return
+17.88%
Copying David Nierengarten's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +17.88% per trade.
1 Year
John NewmanCanaccord Genuity
Success Rate
8/12 ratings generated profit
67%
Average Return
+31.42%
Copying John Newman's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +31.42% per trade.
2 Years
John NewmanCanaccord Genuity
Success Rate
10/12 ratings generated profit
83%
Average Return
+77.60%
Copying John Newman's trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +77.60% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XE9 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
7
8
7
7
6
Buy
3
7
10
14
10
Hold
3
3
1
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
18
18
24
19
In the current month, XE9 has received 16 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. XE9 average Analyst price target in the past 3 months is 26.69.
Each month's total comprises the sum of three months' worth of ratings.

XE9 Financial Forecast

XE9 Earnings Forecast

Next quarter’s earnings estimate for XE9 is -CHF0.32 with a range of -CHF1.01 to CHF0.19. The previous quarter’s EPS was -CHF0.24. XE9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year XE9 has Performed in-line its overall industry.
Next quarter’s earnings estimate for XE9 is -CHF0.32 with a range of -CHF1.01 to CHF0.19. The previous quarter’s EPS was -CHF0.24. XE9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year XE9 has Performed in-line its overall industry.

XE9 Sales Forecast

Next quarter’s sales forecast for XE9 is CHF49.41M with a range of CHF2.61M to CHF96.35M. The previous quarter’s sales results were CHF42.84M. XE9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year XE9 has Performed in-line its overall industry.
Next quarter’s sales forecast for XE9 is CHF49.41M with a range of CHF2.61M to CHF96.35M. The previous quarter’s sales results were CHF42.84M. XE9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year XE9 has Performed in-line its overall industry.

XE9 Stock Forecast FAQ

What is CH:XE9’s average 12-month price target, according to analysts?
Based on analyst ratings, Xencor Inc’s 12-month average price target is 26.69.
    What is CH:XE9’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:XE9, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Xencor Inc a Buy, Sell or Hold?
        Xencor Inc has a consensus rating of Strong Buy, which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.
          What is Xencor Inc’s share price target?
          The average share price target for Xencor Inc is 26.69. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF38.36 ,and the lowest forecast is CHF16.68. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Xencor Inc?
            Xencor Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
              How can I buy shares of Xencor Inc?
              To buy shares of CH:XE9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.